Navigation Links
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Date:9/25/2007

atory affairs, where she oversaw products moving from late-stage research and development into Phase 1 clinical testing. Before that, she served as a team leader for Avastin, Omnitarg and Rapitva in the product portfolio management department. Prior to joining Genentech, Dr. Thomas began her career in the pharmaceutical industry as a toxicologist at Syntex Research. Dr. Thomas received her Ph.D. in toxicology and her B.S. in microbiology from the University of Kentucky.

About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients. The Company's lead product candidate is BSI-201, which is now in early-stage clinical testing for advanced malignancies. The Company will be evaluating the potential of BSI-201 in multiple cancers and expects to file investigational new drug applications on as many as two additional cancer drug candidates in early 2008.


'/>"/>
SOURCE BiPar Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Choosing Lab Quality Management Software
3. Optimizing Quality Control Data Management
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Monitoring Patient Glucose Levels: New Advances in software make it easier
10. New Advances in Gastric Diagnostics: Smaller is Better
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... double-blinded, placebo-controlled Phase 2 clinical trial of MM-141, ... combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel and ... cancer who have high serum levels of free ... leading cause of cancer death in ...
(Date:5/5/2015)... Mich. , May 5, 2015  InfuSystem Holdings, ... infusion pumps and related services for the U.S. healthcare ... financial results on Tuesday, May 12, 2015 after the ... a conference call for investors on Tuesday, May 12, ... quarter performance and results.  To participate in this call, ...
(Date:5/5/2015)... Mass., May 5, 2015   Cynosure, Inc. ... medical devices for aesthetic procedures and precision surgical applications ... ended March 31, 2015. First-Quarter Highlights: ... , Non-GAAP earnings of $0.15 per share; GAAP ... million at March 31, 2015 "Cynosure delivered ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... BEIJING, Aug. 11, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical ... (NYSE: CCM ), the operator of ... centers in China, today announced that it has ... Healthcare ("GEHC"), through its subsidiaries General Electric International ...
... Texas, Aug. 11, 2011 ( RBC Life Sciences : ... proprietary nutritional supplements, wound care and pain management products, today ... ended June 30, 2011, compared to net sales of $7.8 ... reported net earnings of $17,000, or $0.00 per share, compared ...
Cached Medicine Technology:Concord Medical and GE Healthcare Sign MOU for Preferred Partnership in China 2RBC Life Sciences Reports Second Quarter 2011 Results 2RBC Life Sciences Reports Second Quarter 2011 Results 3
(Date:5/5/2015)... 2015 Don’t have time to go ... fitness membership? Don’t know which workout equipment to use? ... order to help members achieve their heath and fitness ... an educational, caused-based wellness company, today announces the launch ... classes led by certified trainers, nutritional information and recipes ...
(Date:5/5/2015)... May 05, 2015 Major League Ultimate ... the belief that ultimate Frisbee™ is home to many ... sport that engages the world. Nike Ultimate Camps’ goal ... creating opportunities for young athletes to learn about the ... MLU the perfect fit. , The Nike Ultimate Camp ...
(Date:5/5/2015)... 05, 2015 Igantia , an ... leads an international initiative to examine key biological milestones ... human lifespan. Scientists at Igantia believe that better ... the initiation of her menstrual cycle to her transition ... aging and, ultimately, extend the lifespan. , By ...
(Date:5/5/2015)... St.Louis MO (PRWEB) May 05, 2015 ... innovative bar flavors in 2014, Walgreens introduces the Cookies ... By focusing on innovation, Extend Nutrition has continually raised ... achieved a great taste, combined with an unprecedented nutritional ... Building on this success, Extend Nutrition will launch additional ...
(Date:5/5/2015)... LENEXA, Kan. (PRWEB) May 05, 2015 ... dedicated exclusively to healthcare providers, has been retained to ... Hospital in Helena, Mont. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... psychiatric treatment facility in Montana to offer both acute ...
Breaking Medicine News(10 mins):Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...
... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...
... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...
... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...
... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...
Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:A Mother's Love Overcomes Poverty's Effect on Health 2Health News:A Mother's Love Overcomes Poverty's Effect on Health 3Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:National registry to track eosinophilic disorders 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
Medicine Products: